CR Sanjiu(000999) 每日经济新闻·2025-03-31 06:49Core Insights - The report highlights China Resources Sanjiu's commitment to sustainable development and ESG practices under its "14th Five-Year Plan" strategy, focusing on green manufacturing and social responsibility while identifying areas for improvement in supply chain ESG management and biodiversity protection [1] Group 1: ESG Highlights - The company has established near-zero carbon park trials, with distributed photovoltaic annual power generation reaching 10.7841 million kWh and a green electricity self-use rate of 92.9% [2] - Smart manufacturing initiatives have led to a 20% increase in production efficiency and a 12% reduction in energy consumption per unit of output at the Guanlan base [2] - The number of national-level green factories has increased to 7, with greenhouse gas emission intensity reduced by 13.58% year-on-year, exceeding the "14th Five-Year Plan" targets [2] - The board of directors shows diversity, with female directors making up 18.18%, and 24 board meetings held throughout the year, with compliance training covering 100% of employees [2] - Supply chain risk management has been strengthened, with 742 suppliers completing ESG audits and anti-corruption training reaching 53,000 participants, with no major corruption incidents reported [2] - Employee training investment totaled 10.432 million yuan, with an average of 30.32 hours of training per employee [2] - The innovative "Three Uncle Health Steward" initiative has conducted over 96 community health public welfare events, benefiting tens of thousands of people [2] Group 2: ESG Shortcomings - Only 43% of subsidiaries have obtained ISO 14001 certification, and the ESG training coverage for suppliers is below 50%, indicating weak environmental compliance capabilities among some small and medium-sized suppliers [3] - The report mentions genetic resource protection but lacks established ecological impact assessment indicators for medicinal herb cultivation [3] - Overall, the company's ESG practices reflect the foresight of a leading player in the traditional Chinese medicine industry, balancing commercial value with social benefits, but still requires breakthroughs in supply chain empowerment and quantitative biodiversity management [3]